Graves病患者^(131)I治疗前后TGAb、TMAb与TPOAb水平变化及其临床观察  

Clinlic Observation of TGAb,TMAb and TPOAb Levels in Patients with Graves' Disease Before and After ^(131)I Therapy

作　　者：李林[1] 廖嘉煦[2] 赵豫琴[1] 

机构地区：[1]成都市第二人民医院,四川成都610017 [2]成都市第六人民医院,四川成都610051

出　　处：《标记免疫分析与临床》2006年第4期213-214,共2页Labeled Immunoassays and Clinical Medicine

摘　　要：通过测定Graves病患者131I治疗前后TGAb、TMAb、TPOAb动态变化,探讨在治疗过程中检测TGAb、TMAb、TPOAb的价值。对73例Graves病患者131I治疗前按TGAb、TMAb、TPOAb水平分为阳性组48例和阴性组25例,并对其治疗后3、6、12和18个月的血清TGAb、TMAb、TPOAb水平进行测量。两组间临床治愈率和未愈率及早发甲低率均有显著性差异(P<0.01)。动态检测Graves病患者131I治疗前后TGAb、TMAb、TPOAb含量变化可以观察疗效、指导治疗、预测复发。To determine serum levels of TGAb,TMAb and TPOAb in patients with Graves＇ disease before and after ^131I therapy, and to investigate value of these parameters in treatment,73 patients were divided into positive group and negative group according to TGAb, TMAb and TPOAb levels before ^131I treatment. Serum levels of TGAb,TMAb and TPOAb were measured by RIA in two groups before and after treatment 3,6,12,18 months respectively. There were significant diferences between two groups（P〈0.01）. The measurement of TGAb, TMAb and TPOAb levels in patients with Graves＇disease was beneficial to monitor treatement and predict prognosis.

关 键 词：GRAVES病 ^131I治疗 甲状腺球蛋白抗体 甲状腺微粒体抗体 甲状腺过氧化物酶抗体 

分 类 号：R581.1[医药卫生—内分泌] R446.62[医药卫生—内科学]